Rozanolixizumab is a humanized monoclonal antibody targeting the human neonatal Fc receptor (FcRn) used to treat generalized myasthenia gravis. Rozonolixizumab itself is an IgG4P, an inactive isotype, to reduce the likelihood of unwanted chain exchange.
- Mechanism
- Curator reviewed · 1 reference
Rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.
- Primary indication
- Rozanolixizumab-noli is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.Curator reviewed · 2 structured indications
- Formula / weight
- 148000.0 Da
- First approval
- Canada, 2025 · United States, 2023 · European Union, 2024
- Also known as
- UCB7665
- Brand names
Resolves to
Compound
Clinical / RWD
Targets
What you can answer from here — as of April 07, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Rozanolixizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account